RNAC: Bullish Engulfing detected on 10 Mar 2026

A bullish engulfing pattern is forming in RNAC at $9.02, positioned within 82 days of a post-collapse recovery structure with a quality score of 31.0. The pattern demonstrates exceptional technical merit: structure scores 15.0/15, volume 12.0/12, and breakout 10.4/13, yielding an overall score of 87.4/98 and 78.06% win probability. Price sits 50.84% above the 52-week low and 52.02% below the 52-week high. Key support anchors at $6.08 with resistance at $9.16, creating a tight consolidation zone critical for breakout validation.

Cartesian Therapeutics reported full-year 2025 financial results on March 09, 2026, the day of pattern detection. Net loss widened to $130.3M as Cartesian ramps Phase 3 AURORA and prepares 2026 TRITON myositis trial, with $126.9M cash expected to last into mid‑2027. Enrollment is on track in the randomized, double-blind Phase 3 AURORA trial (~100 AChR Ab+ MG participants), and the FDA accepted an IND for a seamless adaptive Phase 2 myositis trial (TRITON) up to 50 participants with an interim analysis after 10 participants to inform a potential single pivotal trial in 1H26. Peer-reviewed Nature Medicine publications describe mechanism of action and 12-month durable responses; a biologic-naive subgroup (n=7) showed 57% minimal symptom expression at Month 6 sustained to Month 12. Needham maintained a 'Buy' rating and raised the price target from USD 40.00 to USD 42.00 on January 09, 2026, validating clinical momentum heading into earnings.

The bullish engulfing setup targets a measured move to $9.63 (conservative target), requiring volume confirmation above current 10.68x relative volume ratio. The pattern succeeds if price closes decisively above $9.16 resistance with sustained institutional buying flow—a 78% probability suggests strong structural support. Invalidation triggers at $6.08 support breach, which would represent a technical break of the post-collapse recovery structure and signal mean reversion risk to lower consolidation zones.

Critical headwind: healthcare sector regime is bearish (-0.23 regime score), contrasting the stock's recent 43.63% one-month gain. Recent earnings updates often paired positive cash runway and pipeline news with modestly negative next-day moves, suggesting a tendency for cautious reactions even to constructive updates. RSI at 65.8 approaches overbought thresholds, and beta of 1.54 means 54% higher volatility than broad market. ATR at 9.53% signals elevated daily swings. Phase 3 AURORA trial outcomes remain binary catalysts—enrollment on track, but clinical data won't arrive until later 2026 or 2027. Sector headwinds could pressure valuations despite fundamental progress.